301. Macular dystrophy Clinical trials / Disease details
Clinical trials : 45 / Drugs : 46 - (DrugBank : 12) / Drug target genes : 9 - Drug target pathways : 67
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00060749 (ClinicalTrials.gov) | May 5, 2003 | 9/5/2003 | Effect of DHA Supplements on Macular Function in Patients With Stargardt Macular Dystrophy and Stargardt-like Macular Dystrophy | Investigation of the Effect of Dietary Docosahexaenoic Acid (DHA) Supplementation on Macular Function in Subjects With Autosomal Dominant Stargardt-Like and Autosomal Recessive Stargardt Macular Dystrophy | Macular Degeneration | Drug: Docosahexaenoic Acid (DHA) Dietary Supplement | National Eye Institute (NEI) | NULL | Completed | N/A | N/A | All | 22 | Phase 1 | United States |